No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KBR240621P62500
- 0.45
- +0.15+50.00%
15min DelayClose Jun 14 15:59 ET
0.45High0.45Low
0.45Open0.30Pre Close46 Volume162 Open Interest62.50Strike Price2.07KTurnover22.26%IV2.01%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.45Extrinsic Value100Contract SizeAmericanOptions Type-0.3118Delta0.1925Gamma168.85Leverage Ratio-0.0514Theta-0.0031Rho-52.64Eff Leverage0.0292Vega
Intraday
- 5D
- 1D
News
Looking Into KBR's Recent Short Interest
KBR's (NYSE:KBR) short percent of float has fallen 26.72% since its last report. The company recently reported that it has 2.16 million shares sold short, which is 1.92% of all regular shares that are
KBR's (NYSE:KBR) Investors Will Be Pleased With Their Splendid 177% Return Over the Last Five Years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on a lighter note, a good company can see its share price rise well over
Express News | NASA Selects KBR Wyle Services LLC, Of Fulton, Maryland, To Offer Safety And Mission Assurance Services
Express News | KBR Awarded Follow-on Task Order Supporting B-52 System Program Office
Express News | NYSE Order Imbalance 222126.0 Shares on Buy Side
Express News | NYSE Order Imbalance 125230.0 Shares on Buy Side
Comments
KBR's revenue growth could be seen as a positive sign, despite potential sacrifice of current earnings per share. Future earnings are crucial for shareholders. Despite slower share price gains, the business may continue to perform well.
Those Who Invested in KBR (NYSE:KBR) Five Years Ago Are up 238%Given the upward trend and increased efficiency in KBR's return on capital employed, it appears to show promise. Considering the outstanding shareholder returns over the last five years, it's advisable for investors to explore if these trends will continue.
Sizable insider selling at KBR creating investor caution. Lack of insider buying combined with substantial selling seen as red flag. 1.0% insider ownership doesn't fully dispel concerns.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $ON Semiconductor(ON.US$ - up 3.0%
2. $JPMorgan(JPM.US$ - up 1.8%
3. $Uber Technologies(UBER.US$ - up 1.6%
4. $KBR Inc(KBR.US$ - up 0.8%
5. $Wells Fargo & Co(WFC.US$ - up 0.7%
6. $James Hardie Industries(JHX.US$ - up 0.5%
7. $Celsius Holdings(CELH.US$ - up 0.5%
8....
Gap Ups
1. $ON Semiconductor(ON.US$ - up 3.0%
2. $JPMorgan(JPM.US$ - up 1.8%
3. $Uber Technologies(UBER.US$ - up 1.6%
4. $KBR Inc(KBR.US$ - up 0.8%
5. $Wells Fargo & Co(WFC.US$ - up 0.7%
6. $James Hardie Industries(JHX.US$ - up 0.5%
7. $Celsius Holdings(CELH.US$ - up 0.5%
8....
+9
11
Gainers:
• $Rocket Pharmaceuticals(RCKT.US$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose(GOOS.US$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
• $Rocket Pharmaceuticals(RCKT.US$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose(GOOS.US$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
12
Read more